content: <html>
  
  <head>
  
  <title>China Biologic Products, Inc.: Form S-8 - Prepared by TNT Filings Inc.
  </title>
  </head>
  
  <body>
  
  <div style="border-top-style: solid; border-top-width: 1; padding-top: 1">
    <hr color="#000000" size="5">
  </div>
  <table CELLSPACING="0" BORDER="0" WIDTH="100%" style="border-collapse: collapse" bordercolor="#111111" cellpadding="0">
    <tr>
      <td width="100%"><font FACE="Times New Roman" SIZE="2"><b>
      <p align="center">As filed with the Securities and Exchange Commission on
      May 29, 2008</b></font></td>
    </tr>
    <tr>
      <td width="100%" style="border-bottom-style: double; border-bottom-width: 5">
      <font FACE="Times New Roman" SIZE="2"><b>
      <p align="right">Registration No. 333-</b></font></td>
    </tr>
  </table>
  <b><font FACE="Times New Roman">
  <p align="center"><font size="5">UNITED STATES <br>
  SECURITIES AND EXCHANGE COMMISSION </font></font>
  <font FACE="Times New Roman" SIZE="2"><br>
  Washington, D.C. 20549 </p>
  </font><font FACE="Times New Roman" size="5">
  <p align="center">FORM S-8 </p>
  </font><font FACE="Times New Roman" SIZE="2">
  <p align="center">REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 </p>
  </font><font FACE="Times New Roman" size="6">
  <p align="center">CHINA BIOLOGIC PRODUCTS, INC. <br>
  </font></b><font FACE="Times New Roman" SIZE="2">(Exact name of registrant as
  specified in its Charter) </p>
  </font>
  <table CELLSPACING="0" BORDER="0" WIDTH="100%" cellpadding="0" style="border-collapse: collapse" bordercolor="#111111">
    <tr>
      <td WIDTH="50%" align="center"><font FACE="Times New Roman" SIZE="2"><b>
      Delaware</b></font></td>
      <td WIDTH="50%" align="center"><font FACE="Times New Roman" SIZE="2"><b>
      75-2308816</b></font></td>
    </tr>
    <tr>
      <td WIDTH="50%" align="center" valign="top">
      <font FACE="Times New Roman" SIZE="2">(State or other jurisdiction of <br>
      incorporation or organization)</font></td>
      <td WIDTH="50%" align="center" valign="top">
      <font FACE="Times New Roman" SIZE="2">(I.R.S. Employer Identification No.)</font></td>
    </tr>
  </table>
  <font FACE="Times New Roman" SIZE="2"><b>
  <p ALIGN="center">No. 14 East Hushan Road, <br>
  Taian City, Shandong <br>
  People&#146;s Republic of China, 271000 <br>
  (86) 538-620-2306 <br>
  </b>(Address of Principal Executive Offices) </p>
  </font><font FACE="Times New Roman" size="4">
  <p align="center">China Biologic Products, Inc. <br>
  2008 Equity Incentive Plan </font><b><font FACE="Times New Roman" size="2"><br>
  </font></b><font FACE="Times New Roman" SIZE="2">(Full title of the plan) </p>
  </font>
  <table CELLSPACING="0" BORDER="0" WIDTH="100%" cellpadding="0" style="border-collapse: collapse" bordercolor="#111111">
    <tr>
      <td WIDTH="50%" align="center"><font FACE="Times New Roman" SIZE="2">Chao
      Ming Zhao</font></td>
      <td WIDTH="50%" align="center"><font FACE="Times New Roman" SIZE="2">With a
      copy to:</font></td>
    </tr>
    <tr>
      <td WIDTH="50%" align="center"><font FACE="Times New Roman" SIZE="2">No. 14
      East Hushan Road,</font></td>
      <td WIDTH="50%" align="center"><font FACE="Times New Roman" SIZE="2">Louis
      A. Bevilacqua, Esq.</font></td>
    </tr>
    <tr>
      <td WIDTH="50%" align="center"><font FACE="Times New Roman" SIZE="2">Taian
      City, Shandong</font></td>
      <td WIDTH="50%" align="center"><font FACE="Times New Roman" SIZE="2">Thomas
      M. Shoesmith, Esq.</font></td>
    </tr>
    <tr>
      <td WIDTH="50%" align="center"><font FACE="Times New Roman" SIZE="2">
      People&#146;s Republic of China, 271000</font></td>
      <td WIDTH="50%" align="center"><font FACE="Times New Roman" SIZE="2">Joseph
      R. Tiano, Jr., Esq.</font></td>
    </tr>
    <tr>
      <td WIDTH="50%" align="center"><font FACE="Times New Roman" SIZE="2">
      (86)538-6217079</font></td>
      <td WIDTH="50%" align="center"><font FACE="Times New Roman" SIZE="2">Thelen
      Reid Brown Raysman &amp; Steiner LLP</font></td>
    </tr>
    <tr>
      <td WIDTH="50%" align="center"><font FACE="Times New Roman" SIZE="2">(Name,
      Address and Telephone Number of Agent for Service)</font></td>
      <td WIDTH="50%" align="center"><font FACE="Times New Roman" SIZE="2">701 8<sup>th</sup>
      Street, N.W.</font></td>
    </tr>
    <tr>
      <td WIDTH="50%" align="center">&nbsp;</td>
      <td WIDTH="50%" align="center"><font FACE="Times New Roman" SIZE="2">
      Washington, D.C. 20001</font></td>
    </tr>
    <tr>
      <td WIDTH="50%" align="center">&nbsp;</td>
      <td WIDTH="50%" align="center"><font FACE="Times New Roman" SIZE="2">(202)
      508-4000</font></td>
    </tr>
  </table>
  <font FACE="Times New Roman" SIZE="2">
  <p align="justify" style="text-indent: 5%">Indicate by check mark whether the
  Registrant is a large accelerated filer, an accelerated filer, a non-accelerated
  filer, or a smaller reporting company. See the definitions of &quot;large accelerated
  filer,&quot; &quot;accelerated filer&quot; and &quot;smaller reporting company&quot; in Rule 12b-2 of the
  Exchange Act. (Check one): </p>
  </font>
  <table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse" bordercolor="#111111" width="100%">
    <tr>
      <td width="25%" nowrap>
      <p align="center"><font face="Times New Roman" size="2">Large accelerated
      filer <font face="Wingdings" size="2">&#168;</font></font></td>
      <td width="25%" nowrap>
      <p align="center"><font face="Times New Roman" size="2">Accelerated filer
      <font face="Wingdings" size="2">&#168;</font></font></td>
      <td width="25%" nowrap>
      <p align="center"><font face="Times New Roman" size="2">Non-accelerated
      filer <font face="Wingdings" size="2">&#168;</font></font></td>
      <td width="25%" nowrap>
      <p align="center"><font face="Times New Roman" size="2">Smaller reporting
      company </font><font face="Wingdings 2">Q</font></td>
    </tr>
    <tr>
      <td width="25%" nowrap>&nbsp;</td>
      <td width="25%" nowrap>&nbsp;</td>
      <td width="25%" nowrap><font FACE="Times New Roman" style="font-size: 8pt">
      <p align="center">(Do not check if a <br>
      smaller reporting company)</font></td>
      <td width="25%" nowrap>&nbsp;</td>
    </tr>
  </table>
  <table CELLSPACING="0" BORDER="0" WIDTH="100%" cellpadding="0" style="border-collapse: collapse" bordercolor="#111111">
    <tr>
      <td width="19%" align="center">&nbsp;</td>
      <td align="center" width="1%">&nbsp;</td>
      <td align="center" width="19%">&nbsp;</td>
      <td align="center" width="1%">&nbsp;</td>
      <td align="center" width="19%">&nbsp;</td>
      <td align="center" width="1%">&nbsp;</td>
      <td align="center" width="19%">&nbsp;</td>
      <td align="center" width="1%">&nbsp;</td>
      <td align="center" width="19%">&nbsp;</td>
    </tr>
    <tr>
      <td width="19%" align="center">&nbsp;</td>
      <td align="center" width="1%">&nbsp;</td>
      <td align="center" width="19%">&nbsp;</td>
      <td align="center" width="1%">&nbsp;</td>
      <td align="center" width="19%"><font FACE="Times New Roman" SIZE="2">
      Proposed</font></td>
      <td align="center" width="1%">&nbsp;</td>
      <td align="center" width="19%"><font FACE="Times New Roman" SIZE="2">
      Proposed</font></td>
      <td align="center" width="1%">&nbsp;</td>
      <td align="center" width="19%">&nbsp;</td>
    </tr>
    <tr>
      <td width="19%" align="center"><font FACE="Times New Roman" SIZE="2">Title
      of securities</font></td>
      <td align="center">&nbsp;</td>
      <td align="center" width="19%">&nbsp;</td>
      <td align="center">&nbsp;</td>
      <td align="center" width="19%"><font FACE="Times New Roman" SIZE="2">maximum</font></td>
      <td align="center">&nbsp;</td>
      <td align="center" width="19%"><font FACE="Times New Roman" SIZE="2">maximum</font></td>
      <td align="center">&nbsp;</td>
      <td align="center" width="19%">&nbsp;</td>
    </tr>
    <tr>
      <td align="center"><font FACE="Times New Roman" SIZE="2">to be registered</font></td>
      <td align="center">&nbsp;</td>
      <td align="center"><font FACE="Times New Roman" SIZE="2">Amount to be</font></td>
      <td align="center">&nbsp;</td>
      <td align="center"><font FACE="Times New Roman" SIZE="2">offering price per</font></td>
      <td align="center">&nbsp;</td>
      <td align="center"><font FACE="Times New Roman" SIZE="2">aggregate</font></td>
      <td align="center">&nbsp;</td>
      <td align="center"><font FACE="Times New Roman" SIZE="2">Amount of</font></td>
    </tr>
    <tr>
      <td align="center" style="border-bottom-style: solid; border-bottom-width: 1">
      <font FACE="Times New Roman" SIZE="2">Common stock,</font></td>
      <td align="center">&nbsp;</td>
      <td align="center" style="border-bottom-style: solid; border-bottom-width: 1">
      <font FACE="Times New Roman" SIZE="2">registered<sup>(1)</sup></font></td>
      <td align="center">&nbsp;</td>
      <td align="center" style="border-bottom-style: solid; border-bottom-width: 1">
      <font FACE="Times New Roman" SIZE="2">share<sup>(2)</sup></font></td>
      <td align="center">&nbsp;</td>
      <td align="center" style="border-bottom-style: solid; border-bottom-width: 1">
      <font FACE="Times New Roman" SIZE="2">offering price<sup>(2)</sup></font></td>
      <td align="center">&nbsp;</td>
      <td align="center" style="border-bottom-style: solid; border-bottom-width: 1">
      <font FACE="Times New Roman" SIZE="2">registration fee<sup>(2)</sup></font></td>
    </tr>
    <tr>
      <td align="center" style="border-top-style: solid; border-top-width: 1" bgcolor="#E9F1F8">&nbsp;</td>
      <td align="center" bgcolor="#E9F1F8">&nbsp;</td>
      <td align="center" style="border-top-style: solid; border-top-width: 1" bgcolor="#E9F1F8">&nbsp;</td>
      <td align="center" bgcolor="#E9F1F8">&nbsp;</td>
      <td align="center" style="border-top-style: solid; border-top-width: 1" bgcolor="#E9F1F8">&nbsp;</td>
      <td align="center" bgcolor="#E9F1F8">&nbsp;</td>
      <td align="center" style="border-top-style: solid; border-top-width: 1" bgcolor="#E9F1F8">&nbsp;</td>
      <td align="center" bgcolor="#E9F1F8">&nbsp;</td>
      <td align="center" style="border-top-style: solid; border-top-width: 1" bgcolor="#E9F1F8">&nbsp;</td>
    </tr>
    <tr>
      <td align="center" bgcolor="#E9F1F8"><font FACE="Times New Roman" SIZE="2">
      $0.0001</font></td>
      <td align="center" bgcolor="#E9F1F8">&nbsp;</td>
      <td align="center" bgcolor="#E9F1F8"><font FACE="Times New Roman" SIZE="2">
      5,000,000</font></td>
      <td align="center" bgcolor="#E9F1F8">&nbsp;</td>
      <td align="center" bgcolor="#E9F1F8"><font FACE="Times New Roman" SIZE="2">
      $3.00</font></td>
      <td align="center" bgcolor="#E9F1F8">&nbsp;</td>
      <td align="center" bgcolor="#E9F1F8"><font FACE="Times New Roman" SIZE="2">
      $15,000,000</font></td>
      <td align="center" bgcolor="#E9F1F8">&nbsp;</td>
      <td align="center" bgcolor="#E9F1F8"><font FACE="Times New Roman" SIZE="2">
      $590</font></td>
    </tr>
  </table>
  <font FACE="Times New Roman" style="font-size: 8pt">
  <p ALIGN="justify">(1) </p>
  <p ALIGN="justify" style="margin-left: 5%; margin-top: -25.5pt">Represents
  shares of common stock that may be issued pursuant to the China Biologic
  Products, Inc. 2008 Equity Incentive Plan (the &quot;2008 Plan&quot;). Pursuant to Rule
  416 under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;), this
  Registration Statement shall also cover any additional shares of common stock
  that become issuable under the 2008 Plan by reason of any stock dividend, stock
  split, recapitalization or any other similar transaction effected without the
  receipt of consideration that results in an increase in the number of our
  outstanding shares of common stock. </p>
  <p ALIGN="justify">(2) </p>
  <p ALIGN="justify" style="margin-left: 5%; margin-top: -25.5pt">Estimated solely
  for the purpose of calculating the registration fee in accordance with Rule
  457(h)(1) and (c) under the Securities Act. The proposed maximum aggregate
  offering price is based upon the average of the high and low sale prices of
  China Biologic Products, Inc. common stock as reported on Over-the-Counter
  Bulletin Board (&quot;OTC BB&quot;) on May 15, 2008. </p>
  </font><hr color="#000000" size="5"><p style='page-break-before:always'><font FACE="Times New Roman" SIZE="2"><b>
  <p align="center">PART I </p>
  <p align="center">INFORMATION REQUIRED IN THE SECTION 10(A) PROSPECTUS </p>
  </b>
  <p ALIGN="JUSTIFY" style="text-indent: 5%">The documents containing the
  information specified in Part I will be delivered in accordance with Rule
  428(b)(1) under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;).
  Such documents are not required to be, and are not, filed with the Securities
  and Exchange Commission (the &quot;Commission&quot;), either as part of this Registration
  Statement or as prospectuses or prospectus supplements pursuant to Rule 424
  under the Securities Act. These documents, and the documents incorporated by
  reference in this Registration Statement pursuant to Item 3 of Part II of this
  Form S-8, taken together, constitute a prospectus that meets the requirements of
  Section 10(a) of the Securities Act.<b> </p>
  <p align="center">PART II </p>
  <p align="center">INFORMATION REQUIRED IN THE REGISTRATION STATEMENT </p>
  <p align="justify">ITEM 3.&nbsp;&nbsp;&nbsp;&nbsp; INCORPORATION OF DOCUMENTS BY
  REFERENCE. </p>
  </b>
  <p align="justify" style="text-indent: 5%">The following documents, which have
  been filed by China Biologic Products, Inc. (the &quot;Company&quot;) with the Commission,
  are incorporated in this Registration Statement by reference: </p>
  <p ALIGN="JUSTIFY" style="text-indent: 5%">(a)</font><font FACE="Arial" SIZE="2">
  </font></p>
  <p ALIGN="JUSTIFY" style="text-indent: 10%; margin-top: -25.5pt">
  <font FACE="Times New Roman" SIZE="2">The Company&#146;s Annual Report on Form 10-K
  for the year ended December 31, 2007 filed with the Commission on March 28,
  2008, pursuant to Section 13(a) or 15(d) of the Exchange Act, which includes
  audited financial statements for the Company&#146;s latest fiscal year; </p>
  <p align="justify" style="text-indent: 5%">(b)</font><font FACE="Arial" SIZE="2">
  </font></p>
  <p align="justify" style="text-indent: 10%; margin-top: -25.5pt">
  <font FACE="Times New Roman" SIZE="2">The Company&#146;s prospectus filed with the
  Commission on January 30, 2008 (Commission File No. 333-145877), pursuant to
  Rule 424(b)(3); </p>
  <p align="justify" style="text-indent: 5%">(c)</font><font FACE="Arial" SIZE="2">
  </font></p>
  <p align="justify" style="text-indent: 10%; margin-top: -25.5pt">
  <font FACE="Times New Roman" SIZE="2">All other reports filed pursuant to
  Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year
  covered by the Annual Report referred to in (a) above; and </p>
  <p ALIGN="JUSTIFY" style="text-indent: 5%">(d)</font><font FACE="Arial" SIZE="2">
  </font></p>
  <p ALIGN="JUSTIFY" style="text-indent: 10%; margin-top: -25.5pt">
  <font FACE="Times New Roman" SIZE="2">The description of the Company&#146;s Common
  Stock which is contained in its registration statement on SB-2/A filed with the
  Commission on January 28, 2008, including all amendments and reports filed for
  the purpose of updating such description. </p>
  <p ALIGN="JUSTIFY" style="text-indent: 5%">All documents subsequently filed by
  the Company with the Commission, pursuant to Sections 13(a), 13(c), 14 and 15(d)
  of the Exchange Act, prior to the filing of a post-effective amendment which
  indicates that all securities offered hereby have been sold or which deregisters
  all securities then remaining unsold, shall be deemed to be incorporated by
  reference herein and to be a part hereof from the date of filing of such
  documents. </p>
  <p ALIGN="JUSTIFY" style="text-indent: 5%">Any statement contained in a document
  incorporated or deemed to be incorporated by reference herein shall be deemed to
  be modified or superseded for purposes of this Registration Statement to the
  extent that a statement contained herein or in any other subsequently filed
  document which also is or is deemed to be incorporated by reference herein
  modifies or supersedes such statement. Any statement so modified or superseded
  shall not be deemed, except as so modified or superseded, to constitute a part
  of this Registration Statement. </p>
  <b>
  <p align="justify">ITEM 4.&nbsp;&nbsp;&nbsp;&nbsp; Description of Securities.
  </p>
  </b>
  <p ALIGN="JUSTIFY" style="text-indent: 5%">The description of the Company&#146;s
  Common Stock set forth under the caption &quot;Description of Securities&quot; at page 68
  of the Company&#146;s registration statement on SB-2/A, filed with the Commission on
  January 28, 2008, is hereby incorporated by reference. </p>
  <b>
  <p align="justify">ITEM 5.&nbsp;&nbsp;&nbsp;&nbsp; Interests of Named Experts
  and Counsel. </p>
  </b>
  <p align="justify" style="text-indent: 5%">Not applicable. </p>
  </font>
  <p align="center"><font size="2">2</font></p>
  <hr color="#000000" size="5"><p style='page-break-before:always'><font FACE="Times New Roman" SIZE="2"><b>
  <p align="justify">ITEM 6.&nbsp;&nbsp;&nbsp;&nbsp; Indemnification of Directors
  and Officers. </p>
  </b>
  <p ALIGN="JUSTIFY" style="text-indent: 5%">Our bylaws provide for the
  indemnification of our present and prior directors and officers or any person
  who may have served at our request as a director or officer of another
  corporation in which we own shares of capital stock or of which we are a
  creditor, against expenses actually and necessarily incurred by them in
  connection with the defense of any actions, suits or proceedings in which they,
  or any of them, are made parties, or a party, by reason of being or having been
  director(s) or officer(s) of us or of such other corporation, in the absence of
  negligence or misconduct in the performance of their duties. This
  indemnification policy could result in substantial expenditure by us, which we
  may be unable to recoup. </p>
  <p ALIGN="JUSTIFY" style="text-indent: 5%">Insofar as indemnification by us for
  liabilities arising under the Securities Exchange Act of 1934 may be permitted
  to our directors, officers and controlling persons pursuant to provisions of the
  Articles of Incorporation and Bylaws, or otherwise, we have been advised that in
  the opinion of the Commission, such indemnification is against public policy and
  is, therefore, unenforceable. In the event that a claim for indemnification by
  such director, officer or controlling person of us in the successful defense of
  any action, suit or proceeding is asserted by such director, officer or
  controlling person in connection with the securities being offered, we will,
  unless in the opinion of our counsel the matter has been settled by controlling
  precedent, submit to a court of appropriate jurisdiction the question whether
  such indemnification by us is against public policy as expressed in the Act and
  will be governed by the final adjudication of such issue. </p>
  <p ALIGN="JUSTIFY" style="text-indent: 5%">At the present time, there is no
  pending litigation or proceeding involving a director, officer, employee or
  other agent of ours in which indemnification would be required or permitted. We
  are not aware of any threatened litigation or proceeding which may result in a
  claim for such indemnification. </p>
  <b>
  <p align="justify">ITEM 7.&nbsp;&nbsp;&nbsp;&nbsp; Exemption from Registration
  Claimed. </p>
  </b>
  <p align="justify" style="text-indent: 5%">Not Applicable. </p>
  <b>
  <p align="justify">ITEM 8.&nbsp;&nbsp;&nbsp;&nbsp; EXHIBITS. </p>
  </b>
  <p align="justify" style="text-indent: 5%">Reference is made to the attached
  Exhibit Index, which is incorporated by reference herein. </p>
  <b>
  <p align="justify">ITEM 9.&nbsp;&nbsp;&nbsp;&nbsp; UNDERTAKINGS. </p>
  </b>
  <p align="justify">(A) </p>
  <p align="justify" style="text-indent: 5%; margin-top: -25.5pt">The undersigned
  Registrant hereby undertakes: </p>
  <p align="justify" style="margin-left: 5%">(1) </p>
  <p align="justify" style="text-indent: 10%; margin-top: -25.5pt">To file, during
  any period in which offers or sales are being made, a post-effective amendment
  to this Registration Statement: </p>
  <p align="justify" style="margin-left: 5%">(i) </p>
  <p align="justify" style="text-indent: 5%; margin-left: 5%; margin-top: -25.5pt">
  To include any prospectus required by Section 10(a)(3) of the Securities Act;
  </p>
  <p ALIGN="JUSTIFY" style="margin-left: 5%">(ii) </p>
  <p ALIGN="JUSTIFY" style="text-indent: 5%; margin-left: 5%; margin-top: -25.5pt">
  To reflect in the prospectus any facts or events arising after the effective
  date of this Registration Statement (or the most recent post-effective amendment
  thereof) which, individually or in the aggregate, represent a fundamental change
  in the information set forth in this Registration Statement. Notwithstanding the
  foregoing, any increase or decrease in volume of securities offered (if the
  total dollar value of securities offered would not exceed that which was
  registered) and any deviation from the low or high and of the estimated maximum
  offering range may be reflected in the form of prospectus filed with the SEC
  pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price
  represent no more than 20 percent change in the maximum aggregate offering price
  set forth in the &quot;Calculation of Registration Fee&quot; table in the effective
  Registration Statement; and </p>
  <p align="justify" style="margin-left: 5%">(iii) </p>
  <p align="justify" style="text-indent: 5%; margin-left: 5%; margin-top: -25.5pt">
  To include any additional or changed material information with respect to the
  plan of distribution not previously disclosed in this Registration Statement;
  </p>
  </font>
  <p align="center"><font size="2">3</font></p>
  <hr color="#000000" size="5"><p style='page-break-before:always'><font FACE="Times New Roman" SIZE="2"><i>
  <p align="justify" style="text-indent: 5%">provided, however</i>, that the
  undertakings set forth in paragraphs (a)(1)(i) and (a)(1)(ii) above do not apply
  if the Registration Statement is on Form S-8, and the information required to be
  included in a post-effective amendment by those paragraphs is contained in
  periodic reports filed with or furnished to the SEC by the Registrant pursuant
  to Section 13 or 15(d) of the Exchange Act of 1934 that are incorporated by
  reference in this Registration Statement. </p>
  <p align="justify" style="text-indent: 5%">(2) </p>
  <p align="justify" style="text-indent: 10%; margin-top: -25.5pt">That, for the
  purpose of determining any liability under the Securities Act, each such
  post-effective amendment shall be deemed to be a new registration statement
  relating to the securities offered therein, and the offering of such securities
  at that time shall be deemed to be the initial <i>bona fide</i> offering
  thereof. </p>
  <p align="justify" style="text-indent: 5%">(3) </p>
  <p align="justify" style="text-indent: 10%; margin-top: -25.5pt">To remove from
  registration by means of a post-effective amendment any of the securities being
  registered which remain unsold at the termination of the offering. </p>
  <p align="justify">(B) </p>
  <p align="justify" style="text-indent: 5%; margin-top: -25.5pt">The undersigned
  Registrant hereby undertakes that, for purposes of determining any liability
  under the Securities Act, each filing of the registrant&#146;s annual report pursuant
  to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each
  filing of an employee benefit plan&#146;s annual report pursuant to Section 15(d) of
  the Exchange Act) that is incorporated by reference in this Registration
  Statement shall be deemed to be a new registration statement relating to the
  securities offered therein, and the offering of such securities at that time
  shall be deemed to be the initial bona fide offering thereof. </p>
  <p align="justify">(C) </p>
  <p align="justify" style="text-indent: 5%; margin-top: -25.5pt">Insofar as
  indemnification for liabilities arising under the Securities Act may be
  permitted to directors, officers and controlling persons of the Registrant
  pursuant to the foregoing provisions, or otherwise, the Registrant has been
  advised that in the opinion of the SEC such indemnification is against public
  policy as expressed in the Securities Act and is, therefore, unenforceable. In
  the event that a claim for indemnification against such liabilities (other than
  the payment by the Registrant of expenses incurred or paid by a director,
  officer or controlling person of the Registrant in the successful defense of any
  action, suit or proceeding) is asserted by such director, officer or controlling
  person in connection with the securities being registered, the Registrant will,
  unless in the opinion of its counsel the matter has been settled by controlling
  precedent, submit to a court of appropriate jurisdiction the question whether
  such indemnification by it is against public policy as expressed in the
  Securities Act and will be governed by the final adjudication of such issue. </p>
  </font>
  <p>&nbsp;</p>
  <p align="center"><font size="2">4</font></p>
  <hr color="#000000" size="5"><p style='page-break-before:always'><font FACE="Times New Roman" SIZE="2"><b>
  <p align="center">SIGNATURES </p>
  </b>
  <p ALIGN="JUSTIFY" style="text-indent: 5%">Pursuant to the requirements of the
  Securities Act of 1933, the Registrant certifies that it has reasonable grounds
  to believe that it meets all of the requirements for filing on Form S-8 and has
  duly caused this registration statement to be signed on its behalf by the
  undersigned, thereunto duly authorized, in Taian City, Shandong Province,
  People&#146;s Republic of China, on this 29th day of May, 2008. </p>
  </font>
  <div align="right">
    <table CELLSPACING="0" BORDER="0" WIDTH="50%" style="border-collapse: collapse" bordercolor="#111111" cellpadding="0">
      <tr>
        <td COLSPAN="2"><font FACE="Times New Roman" SIZE="2">CHINA BIOLOGIC
        PRODUCTS, INC.</font></td>
      </tr>
      <tr>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
      </tr>
      <tr>
        <td><font FACE="Times New Roman" SIZE="2">By</font></td>
        <td style="border-bottom-style: solid; border-bottom-width: 1">
        <font FACE="Times New Roman" SIZE="2">/s/ Chao Ming Zhao</font></td>
      </tr>
      <tr>
        <td>&nbsp;</td>
        <td style="border-top-style: solid; border-top-width: 1">
        <font FACE="Times New Roman" SIZE="2">Chao Ming Zhao</font></td>
      </tr>
      <tr>
        <td>&nbsp;</td>
        <td><font FACE="Times New Roman" SIZE="2">Chief Financial Officer</font></td>
      </tr>
    </table>
  </div>
  <font FACE="Times New Roman" SIZE="2"><b>
  <p align="center"><a name="POWER OF ATTORNEY">POWER OF ATTORNEY </a> </p>
  </b>
  <p ALIGN="JUSTIFY" style="text-indent: 5%">Each person whose signature appears
  below constitutes and appoints Chao Ming Zhao his true and lawful
  attorney-in-fact and agent, with full power of substitution and resubstitution,
  for him and in his name, place and stead in any and all capacities, to sign any
  and all amendments (including post-effective amendments) and other documents in
  connection therewith, with the Securities and Exchange Commission, granting unto
  said attorney-in-fact and agent, full power and authority to do and perform each
  and every act and thing requisite and necessary to be done in and about the
  premises, as fully to all intents and purposes as he might or could do in
  person, hereby ratifying and confirming all that said attorney-in-fact and
  agent, or his substitute or substitutes, may lawfully do or cause to be done by
  virtue hereof. </p>
  <p align="justify" style="text-indent: 5%">Pursuant to the requirements of the
  Securities Act of 1933, this Registration Statement has been signed by the
  following persons in the capacities indicated on May 29, 2008. </p>
  </font>
  <table CELLSPACING="0" BORDER="0" WIDTH="100%" cellpadding="0" style="border-collapse: collapse" bordercolor="#111111">
    <tr>
      <td width="50%" colspan="2"><font FACE="Times New Roman" SIZE="2">SIGNATURE</font></td>
      <td width="50%"><font FACE="Times New Roman" SIZE="2">TITLE</font></td>
    </tr>
    <tr>
      <td width="50%" colspan="2">&nbsp;</td>
      <td width="50%">&nbsp;</td>
    </tr>
    <tr>
      <td width="25%" nowrap style="border-bottom-style: solid; border-bottom-width: 1">
      <font FACE="Times New Roman" SIZE="2">/s/ Stanley Wong</font></td>
      <td width="25%" nowrap>&nbsp;</td>
      <td width="50%"><font FACE="Times New Roman" SIZE="2">Chief Executive
      Officer</font></td>
    </tr>
    <tr>
      <td width="50%" colspan="2"><font FACE="Times New Roman" SIZE="2">Stanley
      Wong</font></td>
      <td width="50%"><font FACE="Times New Roman" SIZE="2">(Principal Executive
      Officer)</font></td>
    </tr>
    <tr>
      <td width="50%" colspan="2">&nbsp;</td>
      <td width="50%">&nbsp;</td>
    </tr>
    <tr>
      <td width="25%" nowrap style="border-bottom-style: solid; border-bottom-width: 1">
      <font FACE="Times New Roman" SIZE="2">/s/ Chao Ming Zhao</font></td>
      <td width="25%" nowrap>&nbsp;</td>
      <td width="50%"><font FACE="Times New Roman" SIZE="2">Chief Financial
      Officer, Director</font></td>
    </tr>
    <tr>
      <td width="50%" colspan="2"><font FACE="Times New Roman" SIZE="2">Chao Ming
      Zhao</font></td>
      <td width="50%"><font FACE="Times New Roman" SIZE="2">(Principal Financial
      Officer)</font></td>
    </tr>
    <tr>
      <td width="50%" colspan="2">&nbsp;</td>
      <td width="50%">&nbsp;</td>
    </tr>
    <tr>
      <td width="25%" nowrap style="border-bottom-style: solid; border-bottom-width: 1">
      <font FACE="Times New Roman" SIZE="2">/s/ Siu Ling Chan</font></td>
      <td width="25%" nowrap>&nbsp;</td>
      <td width="50%"><font FACE="Times New Roman" SIZE="2">Chairwoman of the
      Board</font></td>
    </tr>
    <tr>
      <td width="50%" colspan="2"><font FACE="Times New Roman" SIZE="2">Siu Ling
      Chan</font></td>
      <td width="50%">&nbsp;</td>
    </tr>
    <tr>
      <td width="50%" colspan="2">&nbsp;</td>
      <td width="50%">&nbsp;</td>
    </tr>
    <tr>
      <td width="25%" nowrap style="border-bottom-style: solid; border-bottom-width: 1">
      <font FACE="Times New Roman" SIZE="2">/s/ Lin Ling Li</font></td>
      <td width="25%" nowrap>&nbsp;</td>
      <td width="50%"><font FACE="Times New Roman" SIZE="2">Director</font></td>
    </tr>
    <tr>
      <td width="50%" colspan="2"><font FACE="Times New Roman" SIZE="2">Lin Ling
      Li</font></td>
      <td width="50%">&nbsp;</td>
    </tr>
    <tr>
      <td width="50%" colspan="2">&nbsp;</td>
      <td width="50%">&nbsp;</td>
    </tr>
    <tr>
      <td width="25%" nowrap style="border-bottom-style: solid; border-bottom-width: 1">
      <font FACE="Times New Roman" SIZE="2">/s/</font><font FACE="Arial" SIZE="2">
      </font><font FACE="Times New Roman" SIZE="2">Guangli Pang</font></td>
      <td width="25%" nowrap>&nbsp;</td>
      <td width="50%"><font FACE="Times New Roman" SIZE="2">Director</font></td>
    </tr>
    <tr>
      <td width="50%" colspan="2"><font FACE="Times New Roman" SIZE="2">Guangli
      Pang</font></td>
      <td width="50%">&nbsp;</td>
    </tr>
  </table>
  <p align="center"><font size="2">5</font></p>
  <hr color="#000000" size="5"><p style='page-break-before:always'><font FACE="Times New Roman" SIZE="2"><b>
  <p align="center">EXHIBIT INDEX </p>
  </b></font>
  <table CELLSPACING="0" BORDER="0" WIDTH="100%" cellpadding="0" style="border-collapse: collapse" bordercolor="#111111">
    <tr>
      <td width="15%" valign="top"><font FACE="Times New Roman" SIZE="2"><i><b><u>
      Exhibit</u></b></i></font></td>
      <td width="85%" valign="top"><font FACE="Times New Roman" SIZE="2"><i><b><u>
      Description</u></b></i></font></td>
    </tr>
    <tr>
      <td width="15%" valign="top" bgcolor="#E9F1F8">&nbsp;</td>
      <td width="85%" valign="top" bgcolor="#E9F1F8">&nbsp;</td>
    </tr>
    <tr>
      <td width="15%" valign="top" bgcolor="#E9F1F8">
      <font FACE="Times New Roman" SIZE="2">
      <a href="cbioexh51.htm" style="text-decoration: none">5.1</a></font></td>
      <td width="85%" valign="top" bgcolor="#E9F1F8">
      <font FACE="Times New Roman" SIZE="2">
      <p align="justify"><a href="cbioexh51.htm" style="text-decoration: none">Opinion of Thelen Reid Brown Raysman &amp; Steiner, LLP</a></font></td>
    </tr>
    <tr>
      <td width="15%" valign="top">&nbsp;</td>
      <td width="85%" valign="top">
      <p align="justify">&nbsp;</td>
    </tr>
    <tr>
      <td width="15%" valign="top"><font FACE="Times New Roman" SIZE="2">10.1</font></td>
      <td width="85%" valign="top"><font FACE="Times New Roman" SIZE="2">
      <p align="justify">China Biologic Products, Inc. Equity Incentive Plan
      (incorporated by reference to Exhibit 10.1 to the Company&#146;s current report
      on Form 8-K filed on May 13, 2008)</font></td>
    </tr>
    <tr>
      <td width="15%" valign="top" bgcolor="#E9F1F8">&nbsp;</td>
      <td width="85%" valign="top" bgcolor="#E9F1F8">
      <p align="justify">&nbsp;</td>
    </tr>
    <tr>
      <td width="15%" valign="top" bgcolor="#E9F1F8">
      <font FACE="Times New Roman" SIZE="2">
      <a href="cbioexh231.htm" style="text-decoration: none">23.1</a></font></td>
      <td width="85%" valign="top" bgcolor="#E9F1F8">
      <font FACE="Times New Roman" SIZE="2">
      <p align="justify"><a href="cbioexh231.htm" style="text-decoration: none">Consent of Moore Stephens Wurth Frazer and Torbet, LLP,
      Certified Public Accountants</a></font></td>
    </tr>
    <tr>
      <td width="15%" valign="top">&nbsp;</td>
      <td width="85%" valign="top">
      <p align="justify">&nbsp;</td>
    </tr>
    <tr>
      <td width="15%" valign="top"><font FACE="Times New Roman" SIZE="2">
      <a href="cbioexh51.htm" style="text-decoration: none">23.2</a></font></td>
      <td width="85%" valign="top"><font FACE="Times New Roman" SIZE="2">
      <p align="justify"><a href="cbioexh51.htm" style="text-decoration: none">Consent of Thelen Reid Brown Raysman &amp; Steiner, LLP
      (included in Exhibit 5.1)</a></font></td>
    </tr>
    <tr>
      <td width="15%" valign="top" bgcolor="#E9F1F8">&nbsp;</td>
      <td width="85%" valign="top" bgcolor="#E9F1F8">
      <p align="justify">&nbsp;</td>
    </tr>
    <tr>
      <td width="15%" valign="top" bgcolor="#E9F1F8">
      <font FACE="Times New Roman" SIZE="2">
      <a href="#POWER OF ATTORNEY" style="text-decoration: none">24.1</a></font></td>
      <td width="85%" valign="top" bgcolor="#E9F1F8">
      <font FACE="Times New Roman" SIZE="2">
      <p align="justify">
      <a href="#POWER OF ATTORNEY" style="text-decoration: none">Power of Attorney (included on the Signature Page to this
      Registration Statement)</a></font></td>
    </tr>
    <tr>
      <td width="15%" valign="top">&nbsp;</td>
      <td width="85%" valign="top">&nbsp;</td>
    </tr>
    <tr>
      <td width="15%" valign="top">&nbsp;</td>
      <td width="85%" valign="top">&nbsp;</td>
    </tr>
    <tr>
      <td width="15%" valign="top">&nbsp;</td>
      <td width="85%" valign="top">&nbsp;</td>
    </tr>
  </table>
  <hr color="#000000" size="5">
  
  </body>
  
  </html>
metadata_documents: [{"type": "S-8", "sequence": "1", "filename": "cbiofs8.htm", "description": "FORM S-8", "secsgml_size_bytes": 34807}]
metadata_filer: {"company-data": {"conformed-name": "China Biologic Products, Inc.", "cik": "0001369868", "assigned-sic": "2836", "irs-number": "000000000", "state-of-incorporation": "F4", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-151263", "film-number": "08867150"}, "business-address": {"street1": "NO.14 EAST HUSHAN ROAD", "city": "TAI'AN CITY, SHANDONG", "state": "F4", "zip": "271000", "phone": "86-538-620-3897"}, "mail-address": {"street1": "NO.14 EAST HUSHAN ROAD", "city": "TAI'AN CITY, SHANDONG", "state": "F4", "zip": "271000"}, "former-company": {"former-conformed-name": "GRC Holdings, Inc.", "date-changed": "20060721"}}
text: China Biologic Products, Inc.: Form S-8 - Prepared by TNT Filings Inc.
  As filed with the Securities and Exchange Commission on
      May 29, 2008
  Registration No. 333-
  UNITED STATES
  SECURITIES AND EXCHANGE COMMISSION
  Washington, D.C. 20549
  FORM S-8
  REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
  CHINA BIOLOGIC PRODUCTS, INC.
  (Exact name of registrant as
  specified in its Charter)
  Delaware
  75-2308816
  (State or other jurisdiction of
  incorporation or organization)
  (I.R.S. Employer Identification No.)
  No. 14 East Hushan Road,
  Taian City, Shandong
  People's Republic of China, 271000
  (86) 538-620-2306
  (Address of Principal Executive Offices)
  China Biologic Products, Inc.
  2008 Equity Incentive Plan
  (Full title of the plan)
  Chao
      Ming Zhao
  With a
      copy to:
  No. 14
      East Hushan Road,
  Louis
      A. Bevilacqua, Esq.
  Taian
      City, Shandong
  Thomas
      M. Shoesmith, Esq.
  People's Republic of China, 271000
  Joseph
      R. Tiano, Jr., Esq.
  (86)538-6217079
  Thelen
      Reid Brown Raysman & Steiner LLP
  (Name,
      Address and Telephone Number of Agent for Service)
  701 8
  th
  Street, N.W.
  Washington, D.C. 20001
  (202)
      508-4000
  Indicate by check mark whether the
  Registrant is a large accelerated filer, an accelerated filer, a non-accelerated
  filer, or a smaller reporting company. See the definitions of "large accelerated
  filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the
  Exchange Act. (Check one):
  Large accelerated
      filer
  ¨
  Accelerated filer
  ¨
  Non-accelerated
      filer
  ¨
  Smaller reporting
      company
  Q
  (Do not check if a
  smaller reporting company)
  Proposed
  Proposed
  Title
      of securities
  maximum
  maximum
  to be registered
  Amount to be
  offering price per
  aggregate
  Amount of
  Common stock,
  registered
  (1)
  share
  (2)
  offering price
  (2)
  registration fee
  (2)
  $0.0001
  5,000,000
  $3.00
  $15,000,000
  $590
  (1)
  Represents
  shares of common stock that may be issued pursuant to the China Biologic
  Products, Inc. 2008 Equity Incentive Plan (the "2008 Plan"). Pursuant to Rule
  416 under the Securities Act of 1933, as amended (the "Securities Act"), this
  Registration Statement shall also cover any additional shares of common stock
  that become issuable under the 2008 Plan by reason of any stock dividend, stock
  split, recapitalization or any other similar transaction effected without the
  receipt of consideration that results in an increase in the number of our
  outstanding shares of common stock.
  (2)
  Estimated solely
  for the purpose of calculating the registration fee in accordance with Rule
  457(h)(1) and (c) under the Securities Act. The proposed maximum aggregate
  offering price is based upon the average of the high and low sale prices of
  China Biologic Products, Inc. common stock as reported on Over-the-Counter
  Bulletin Board ("OTC BB") on May 15, 2008.
  PART I
  INFORMATION REQUIRED IN THE SECTION 10(A) PROSPECTUS
  The documents containing the
  information specified in Part I will be delivered in accordance with Rule
  428(b)(1) under the Securities Act of 1933, as amended (the "Securities Act").
  Such documents are not required to be, and are not, filed with the Securities
  and Exchange Commission (the "Commission"), either as part of this Registration
  Statement or as prospectuses or prospectus supplements pursuant to Rule 424
  under the Securities Act. These documents, and the documents incorporated by
  reference in this Registration Statement pursuant to Item 3 of Part II of this
  Form S-8, taken together, constitute a prospectus that meets the requirements of
  Section 10(a) of the Securities Act.
  PART II
  INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
  ITEM 3.     INCORPORATION OF DOCUMENTS BY
  REFERENCE.
  The following documents, which have
  been filed by China Biologic Products, Inc. (the "Company") with the Commission,
  are incorporated in this Registration Statement by reference:
  (a)
  The Company's Annual Report on Form 10-K
  for the year ended December 31, 2007 filed with the Commission on March 28,
  2008, pursuant to Section 13(a) or 15(d) of the Exchange Act, which includes
  audited financial statements for the Company's latest fiscal year;
  (b)
  The Company's prospectus filed with the
  Commission on January 30, 2008 (Commission File No. 333-145877), pursuant to
  Rule 424(b)(3);
  (c)
  All other reports filed pursuant to
  Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year
  covered by the Annual Report referred to in (a) above; and
  (d)
  The description of the Company's Common
  Stock which is contained in its registration statement on SB-2/A filed with the
  Commission on January 28, 2008, including all amendments and reports filed for
  the purpose of updating such description.
  All documents subsequently filed by
  the Company with the Commission, pursuant to Sections 13(a), 13(c), 14 and 15(d)
  of the Exchange Act, prior to the filing of a post-effective amendment which
  indicates that all securities offered hereby have been sold or which deregisters
  all securities then remaining unsold, shall be deemed to be incorporated by
  reference herein and to be a part hereof from the date of filing of such
  documents.
  Any statement contained in a document
  incorporated or deemed to be incorporated by reference herein shall be deemed to
  be modified or superseded for purposes of this Registration Statement to the
  extent that a statement contained herein or in any other subsequently filed
  document which also is or is deemed to be incorporated by reference herein
  modifies or supersedes such statement. Any statement so modified or superseded
  shall not be deemed, except as so modified or superseded, to constitute a part
  of this Registration Statement.
  ITEM 4.     Description of Securities.
  The description of the Company's
  Common Stock set forth under the caption "Description of Securities" at page 68
  of the Company's registration statement on SB-2/A, filed with the Commission on
  January 28, 2008, is hereby incorporated by reference.
  ITEM 5.     Interests of Named Experts
  and Counsel.
  Not applicable.
  2
  ITEM 6.     Indemnification of Directors
  and Officers.
  Our bylaws provide for the
  indemnification of our present and prior directors and officers or any person
  who may have served at our request as a director or officer of another
  corporation in which we own shares of capital stock or of which we are a
  creditor, against expenses actually and necessarily incurred by them in
  connection with the defense of any actions, suits or proceedings in which they,
  or any of them, are made parties, or a party, by reason of being or having been
  director(s) or officer(s) of us or of such other corporation, in the absence of
  negligence or misconduct in the performance of their duties. This
  indemnification policy could result in substantial expenditure by us, which we
  may be unable to recoup.
  Insofar as indemnification by us for
  liabilities arising under the Securities Exchange Act of 1934 may be permitted
  to our directors, officers and controlling persons pursuant to provisions of the
  Articles of Incorporation and Bylaws, or otherwise, we have been advised that in
  the opinion of the Commission, such indemnification is against public policy and
  is, therefore, unenforceable. In the event that a claim for indemnification by
  such director, officer or controlling person of us in the successful defense of
  any action, suit or proceeding is asserted by such director, officer or
  controlling person in connection with the securities being offered, we will,
  unless in the opinion of our counsel the matter has been settled by controlling
  precedent, submit to a court of appropriate jurisdiction the question whether
  such indemnification by us is against public policy as expressed in the Act and
  will be governed by the final adjudication of such issue.
  At the present time, there is no
  pending litigation or proceeding involving a director, officer, employee or
  other agent of ours in which indemnification would be required or permitted. We
  are not aware of any threatened litigation or proceeding which may result in a
  claim for such indemnification.
  ITEM 7.     Exemption from Registration
  Claimed.
  Not Applicable.
  ITEM 8.     EXHIBITS.
  Reference is made to the attached
  Exhibit Index, which is incorporated by reference herein.
  ITEM 9.     UNDERTAKINGS.
  (A)
  The undersigned
  Registrant hereby undertakes:
  (1)
  To file, during
  any period in which offers or sales are being made, a post-effective amendment
  to this Registration Statement:
  (i)
  To include any prospectus required by Section 10(a)(3) of the Securities Act;
  (ii)
  To reflect in the prospectus any facts or events arising after the effective
  date of this Registration Statement (or the most recent post-effective amendment
  thereof) which, individually or in the aggregate, represent a fundamental change
  in the information set forth in this Registration Statement. Notwithstanding the
  foregoing, any increase or decrease in volume of securities offered (if the
  total dollar value of securities offered would not exceed that which was
  registered) and any deviation from the low or high and of the estimated maximum
  offering range may be reflected in the form of prospectus filed with the SEC
  pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price
  represent no more than 20 percent change in the maximum aggregate offering price
  set forth in the "Calculation of Registration Fee" table in the effective
  Registration Statement; and
  (iii)
  To include any additional or changed material information with respect to the
  plan of distribution not previously disclosed in this Registration Statement;
  3
  provided, however
  , that the
  undertakings set forth in paragraphs (a)(1)(i) and (a)(1)(ii) above do not apply
  if the Registration Statement is on Form S-8, and the information required to be
  included in a post-effective amendment by those paragraphs is contained in
  periodic reports filed with or furnished to the SEC by the Registrant pursuant
  to Section 13 or 15(d) of the Exchange Act of 1934 that are incorporated by
  reference in this Registration Statement.
  (2)
  That, for the
  purpose of determining any liability under the Securities Act, each such
  post-effective amendment shall be deemed to be a new registration statement
  relating to the securities offered therein, and the offering of such securities
  at that time shall be deemed to be the initial
  bona fide
  offering
  thereof.
  (3)
  To remove from
  registration by means of a post-effective amendment any of the securities being
  registered which remain unsold at the termination of the offering.
  (B)
  The undersigned
  Registrant hereby undertakes that, for purposes of determining any liability
  under the Securities Act, each filing of the registrant's annual report pursuant
  to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each
  filing of an employee benefit plan's annual report pursuant to Section 15(d) of
  the Exchange Act) that is incorporated by reference in this Registration
  Statement shall be deemed to be a new registration statement relating to the
  securities offered therein, and the offering of such securities at that time
  shall be deemed to be the initial bona fide offering thereof.
  (C)
  Insofar as
  indemnification for liabilities arising under the Securities Act may be
  permitted to directors, officers and controlling persons of the Registrant
  pursuant to the foregoing provisions, or otherwise, the Registrant has been
  advised that in the opinion of the SEC such indemnification is against public
  policy as expressed in the Securities Act and is, therefore, unenforceable. In
  the event that a claim for indemnification against such liabilities (other than
  the payment by the Registrant of expenses incurred or paid by a director,
  officer or controlling person of the Registrant in the successful defense of any
  action, suit or proceeding) is asserted by such director, officer or controlling
  person in connection with the securities being registered, the Registrant will,
  unless in the opinion of its counsel the matter has been settled by controlling
  precedent, submit to a court of appropriate jurisdiction the question whether
  such indemnification by it is against public policy as expressed in the
  Securities Act and will be governed by the final adjudication of such issue.
  4
  SIGNATURES
  Pursuant to the requirements of the
  Securities Act of 1933, the Registrant certifies that it has reasonable grounds
  to believe that it meets all of the requirements for filing on Form S-8 and has
  duly caused this registration statement to be signed on its behalf by the
  undersigned, thereunto duly authorized, in Taian City, Shandong Province,
  People's Republic of China, on this 29th day of May, 2008.
  CHINA BIOLOGIC
        PRODUCTS, INC.
  By
  /s/ Chao Ming Zhao
  Chao Ming Zhao
  Chief Financial Officer
  POWER OF ATTORNEY
  Each person whose signature appears
  below constitutes and appoints Chao Ming Zhao his true and lawful
  attorney-in-fact and agent, with full power of substitution and resubstitution,
  for him and in his name, place and stead in any and all capacities, to sign any
  and all amendments (including post-effective amendments) and other documents in
  connection therewith, with the Securities and Exchange Commission, granting unto
  said attorney-in-fact and agent, full power and authority to do and perform each
  and every act and thing requisite and necessary to be done in and about the
  premises, as fully to all intents and purposes as he might or could do in
  person, hereby ratifying and confirming all that said attorney-in-fact and
  agent, or his substitute or substitutes, may lawfully do or cause to be done by
  virtue hereof.
  Pursuant to the requirements of the
  Securities Act of 1933, this Registration Statement has been signed by the
  following persons in the capacities indicated on May 29, 2008.
  SIGNATURE
  TITLE
  /s/ Stanley Wong
  Chief Executive
      Officer
  Stanley
      Wong
  (Principal Executive
      Officer)
  /s/ Chao Ming Zhao
  Chief Financial
      Officer, Director
  Chao Ming
      Zhao
  (Principal Financial
      Officer)
  /s/ Siu Ling Chan
  Chairwoman of the
      Board
  Siu Ling
      Chan
  /s/ Lin Ling Li
  Director
  Lin Ling
      Li
  /s/
  Guangli Pang
  Director
  Guangli
      Pang
  5
  EXHIBIT INDEX
  Exhibit
  Description
  5.1
  Opinion of Thelen Reid Brown Raysman & Steiner, LLP
  10.1
  China Biologic Products, Inc. Equity Incentive Plan
      (incorporated by reference to Exhibit 10.1 to the Company's current report
      on Form 8-K filed on May 13, 2008)
  23.1
  Consent of Moore Stephens Wurth Frazer and Torbet, LLP,
      Certified Public Accountants
  23.2
  Consent of Thelen Reid Brown Raysman & Steiner, LLP
      (included in Exhibit 5.1)
  24.1
  Power of Attorney (included on the Signature Page to this
      Registration Statement)